Blueprint Medicines, headquartered in Cambridge, Massachusetts, develops precision therapies for cancer and blood disorders, employing 645 fulltime staff. It has approved medicines like AYVAKIT and GAVRETO, with ongoing research in various cancers.
Blueprint Medicines (BPMC) reported a negative EPS surprise in its most recent quarterly earnings. For the most recent quarter, Blueprint Medicines's actual EPS was -$0.74, missing the estimate of -$0.54 per share, resulting in a -38.06% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
